{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:12Z","timestamp":1793045472092,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T00:00:00Z","timestamp":1631836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["205879"],"award-info":[{"award-number":["205879"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004315","name":"GlaxoSmithKline USA Rockville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["144160"],"award-info":[{"award-number":["144160"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","award":["296306"],"award-info":[{"award-number":["296306"]}],"id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.gastha.2021.09.005","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T10:25:58Z","timestamp":1643883958000},"page":"106-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6433-5956","authenticated-orcid":false,"given":"Hin Hin","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishi H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Haylock-Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Doucette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mang M.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Elkhashab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Minuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Fung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alnoor","family":"Ramji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla S.","family":"Coffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2021.09.005_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s00535-016-1264-3","article-title":"Nonalcoholic fatty liver disease in Asia: emerging perspectives","volume":"52","author":"Seto","year":"2017","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.gastha.2021.09.005_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.12619","article-title":"High prevalence of non-alcoholic fatty liver disease in the Chinese: results from the Hong Kong liver health census","volume":"35","author":"Fung","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MEG.0b013e328326792e","article-title":"Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors","volume":"21","author":"Minkari","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib4","first-page":"35","article-title":"Prevalence of hepatic steatosis in chronic hepatitis B patients and in its association with disease severity","volume":"4","author":"Lesmana","year":"2012","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.gastha.2021.09.005_bib5","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/hep.20466","article-title":"Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity","volume":"40","author":"Browning","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2021.09.005_bib6","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gastha.2021.09.005_bib7","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1499-3872(16)60144-3","article-title":"High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatitis B","volume":"16","author":"Chen","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1177\/2050640617751252","article-title":"Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome","volume":"6","author":"Cai","year":"2018","journal-title":"UEG J"},{"key":"10.1016\/j.gastha.2021.09.005_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cgh.2017.09.044","article-title":"Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B","volume":"16","author":"Seto","year":"2018","journal-title":"Clin Gastro Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3350\/cmh.2018.0040","article-title":"Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"25","author":"Lee","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/jvh.12766","article-title":"Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study","volume":"25","author":"Hui","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2021.09.005_bib13","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","article-title":"Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study","volume":"51","author":"Dasarathy","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10620-014-3429-3","article-title":"Fat and fiber: how the controlled attenuation parameter complements noninvasive assessment of liver fibrosis","volume":"60","author":"Wong","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2021.09.005_bib15","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","article-title":"Controlled attenuation parameter (CAP): a novel VCTE guided ultrasound attenuation measurement of the evaluation of hepatic steatosis preliminary study and validation in a cohort of patients with chronic liver disease from various causes","volume":"36","author":"Sasso","year":"2010","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.gastha.2021.09.005_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinre.2011.08.001","article-title":"The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan","volume":"36","author":"Sasso","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastha.2021.09.005_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2893.2011.01534.x","article-title":"Novel controlled attenuation parameter for non-invasive assessment of steatosis using Fibroscan\u00ae: validation in chronic hepatitis B","volume":"19","author":"Sasso","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2021.09.005_bib19","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10620-014-3341-x","article-title":"Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan\u00ae: validation in chronic Hepatitis B","volume":"60","author":"Mi","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2021.09.005_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","article-title":"Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load","volume":"1","author":"Peleg","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.gastha.2021.09.005_bib21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/jvh.13361","article-title":"Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B","volume":"27","author":"Wong","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2021.09.005_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.12282","article-title":"Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population","volume":"34","author":"Chon","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","article-title":"Controlled attenuation parameter (CAP): a non-invasive method for the detection of hepatic steatosis based on transient elastography","volume":"32","author":"Myers","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib24","doi-asserted-by":"crossref","first-page":"E610","DOI":"10.9778\/cmajo.20190103","article-title":"Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network","volume":"7","author":"Coffin","year":"2019","journal-title":"CMAJ Open"},{"key":"10.1016\/j.gastha.2021.09.005_bib25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3138\/canlivj.2018-0008","article-title":"Management of hepatitis B virus infection: 2018 guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada","volume":"1","author":"Coffin","year":"2018","journal-title":"Can Liver J"},{"key":"10.1016\/j.gastha.2021.09.005_bib26","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/s41598-020-71723-2","article-title":"Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study","volume":"10","author":"Parente","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.gastha.2021.09.005_bib27","series-title":"The liver meeting 2021 Nov 12-15","article-title":"Molecular and clinical epidemiology of hepatitis D virus infection in Canada [abstract]","author":"Osiowy","year":"2021"},{"key":"10.1016\/j.gastha.2021.09.005_bib28","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/jvh.13453","article-title":"Distinct hepatitis B and HIV co-infected populations in Canada","volume":"28","author":"Cooper","year":"2021","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.gastha.2021.09.005_bib29","series-title":"The liver meeting; 2021 Nov 12-15","author":"Coffin","year":"2021"},{"key":"10.1016\/j.gastha.2021.09.005_bib30","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.12282","article-title":"Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population","volume":"34","author":"Shen","year":"2014","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12916-020-01713-8","article-title":"Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches","volume":"18","author":"Soto-Angona","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.gastha.2021.09.005_bib32","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/17474124.2018.1460202","article-title":"The relationship between obesity and the severity of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Lu","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib33","first-page":"89","article-title":"Metabolic syndrome and risk factors for non-alcoholic fatty liver disease","volume":"49","author":"De Araujo Souza","year":"2012","journal-title":"Arch Gastroenterol"},{"key":"10.1016\/j.gastha.2021.09.005_bib34","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/hep.30857","article-title":"Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic Hepatitis B","volume":"71","author":"Choi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.gastha.2021.09.005_bib35","doi-asserted-by":"crossref","first-page":"101483","DOI":"10.1016\/j.clinre.2020.06.009","article-title":"Concurrence of HBV infection and non-alcoholic fatty liver disease is associated with higher prevalence of chronic kidney disease","volume":"45","author":"Lin","year":"2021","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastha.2021.09.005_bib36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/liv.14369","article-title":"Chronic hepatitis B and non-alcoholic fatty liver disease: conspirators or competitors?","volume":"40","author":"Zhang","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.gastha.2021.09.005_bib37","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10620-012-2343-9","article-title":"Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without","volume":"58","author":"Chu","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2021.09.005_bib38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s10620-012-2441-8","article-title":"The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection: fact or fiction?","volume":"58","author":"Fung","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastha.2021.09.005_bib39","first-page":"38","article-title":"Hepatitis B and concomitant hepatic steatosis","volume":"5","author":"Lim","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.gastha.2021.09.005_bib40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/j.1440-1746.2011.06801.x","article-title":"Hepatic steatosis in hepatitis B virus infected patients: a meta-analysis of risk factors and comparison with hepatitis C infected patients","volume":"26","author":"Machado","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2021.09.005_bib41","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1053\/j.gastro.2007.03.039","article-title":"Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PRAR-gamma","volume":"132","author":"Kim","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2021.09.005_bib42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/BJ20081336","article-title":"Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXR alpha","volume":"416","author":"Kim","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.gastha.2021.09.005_bib43","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","article-title":"Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B","volume":"73","author":"Mak","year":"2020","journal-title":"J\u00a0Hepatol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572321000108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572321000108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:04:22Z","timestamp":1778933062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572321000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2772572321000108"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2021.09.005","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}